Press Room

Visit our press room for current and past releases about our company.
February 13, 2013

Lab Bio-Medic, Algorithme Pharma Sign Partnership

Montreal, February 14, 2013 – Lab Bio-Medic and Algorithme Pharma are pleased to announce that they have signed a partnership agreement for the delivery of biomedical analysis required as part of clinical research projects conducted on behalf of pharmaceutical and biotech customers of this world leader in the conduct of Phase I / IIa and bioequivalence clinical trials.  

January 27, 2013

Algorithme Pharma and SQI Diagnostics to Develop Multiplex Heparin Immunogenicity Assay

Laval, Quebec, January 25, 2013 – Algorithme Pharma and SQI Diagnostics’ (“SQI”) announced that they are using SQI’s Ig_PlexTM multiplexing technology to develop a multiplex proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) compounds.

February 07, 2012

Critical Outcome Technologies Inc. announced today it has engaged Algorithme Pharma Inc.

London, Ontario: Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced today that it has engaged Algorithme Pharma Inc. (Algorithme) of Montreal, Canada, aninternationally recognized contract research organization, to develop and validate the final quantitativemethod to be used for preclinical and Phase 1 studies for COTI‐2. 

November 02, 2011

RedHill Biopharma engages with Algorithme Pharma

RedHill Biopharma is preparing for an advanced clinical trial with RHB-102, a drug for the prevention of nausea and vomiting in cancer patients undergoing chemotherapy and radiotherapy.

The company reported an engagement with a Canadian CRO, Algorithme Pharma, for the execution of the RHB-102 clinical trial.

The drug market for Serotonin Receptor Inhibitors is estimated at $700 million in the US alone.

September 12, 2011

Thrasos initiates Phase I clinical trial for THR-184 in acute kidney injury

MONTREAL, September 13, 2011 – Thrasos Innovation, Inc. today announced that it has initiated a Phase 1 clinical trial to study the safety and tolerability of THR-184, which the Company is developing for the treatment of Acute Kidney Injury (AKI) post-surgery. The Phase 1 study is being conducted by Algorithme Pharma of Laval, Quebec, Canada.

Pages